The Cooper Companies, Inc. COO Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Coopersurgical Segment | $358M+8.8% | $329M-7.4% | $355.4M+3.9% | $341.9M+2.8% | $332.7M+4.4% | |
| Coopervision Segment | $723.5M+4.1% | $695.1M-2.1% | $709.7M-1.2% | $718.4M+7.3% | $669.6M+3.6% | |
| Total Assets by Business | ||||||
| CooperSurgical | $4.62B+0.7% | $4.58B-0.8% | $4.62B-1.1% | $4.67B-2.0% | $4.76B-0.3% | |
| CooperVision | $7.63B-0.4% | $7.66B+0.7% | $7.6B+1.2% | $7.51B+0.7% | $7.46B+2.8% | |
| Operating Income (Loss) by Business | ||||||
| CooperSurgical | -$225M-940% | $26.8M+624% | $3.7M+188% | -$4.2M-118% | $23.7M+17.3% | |
| CooperVision | $215.6M+2.6% | $210.2M+34.1% | $156.7M-22.7% | $202.6M+8.7% | $186.4M+1.4% | |
| Cost of Sales by Business | ||||||
| CooperSurgical | $116.7M+8.0% | $108.1M— | —— | —— | $107.6M+8.1% | |
| CooperVision | $229.4M+3.9% | $220.8M— | —— | —— | $215.6M+5.2% | |
| Selling, general and administrative expense by Business | ||||||
| CooperSurgical | $402.4M+213% | $128.4M— | —— | —— | $136.8M+0.7% | |
| CooperVision | $252.2M+6.1% | $237.6M— | —— | —— | $236.9M+3.0% | |
| Research and development expense by Business | ||||||
| CooperSurgical | $20.4M-6.8% | $21.9M— | —— | —— | $19.9M+9.3% | |
| CooperVision | $22.1M-1.3% | $22.4M— | —— | —— | $25.6M+13.8% | |
| Amortization of intangibles by Business | ||||||
| CooperSurgical | $43.5M-0.7% | $43.8M— | —— | —— | $44.7M-0.2% | |
| CooperVision | $4.2M+2.4% | $4.1M— | —— | —— | $5.1M+6.3% | |
| Depreciation expense by Business | ||||||
| CooperSurgical | $6.5M0.0% | $6.5M— | —— | —— | $5.9M-3.3% | |
| CooperVision | $41.3M+0.5% | $41.1M— | —— | —— | $37.1M+5.1% | |
| CapEx by Business | ||||||
| CooperSurgical | $9.8M+22.5% | $8M— | —— | —— | $8.7M-37.0% | |
| CooperVision | $76.6M-18.7% | $94.2M— | —— | —— | $69.4M-8.2% | |
| Net Sales by Product | ||||||
| Fertility | $143.8M+13.6% | $126.6M-10.1% | $140.9M+2.8% | $137.1M+8.0% | $126.9M+6.0% | |
| Office and surgical | $214.2M+5.8% | $202.4M-5.6% | $214.5M+4.7% | $204.8M-0.5% | $205.8M+3.5% | |
| Sphere, other | $358.6M+4.3% | $343.9M-5.8% | $365M+1.5% | $359.6M+5.4% | $341.2M+4.4% | |
| Toric and multifocal | $364.9M+3.9% | $351.2M+1.9% | $344.7M-3.9% | $358.8M+9.3% | $328.4M+2.8% | |
| Net Sales by Geography | ||||||
| Europe | $341.6M+4.7% | $326.4M-77.6% | $1.46B+324% | $343.1M+17.5% | $291.9M+1.5% | |
| Rest of world | $192.1M+4.5% | $183.8M— | —— | $201M+3.0% | $195.2M+8.0% | |
| United States | $547.8M+6.6% | $513.9M-2.3% | $526.2M+1.9% | $516.2M+0.2% | $515.2M+3.8% | |
| Total by Geography | ||||||
| Europe | $445.7M-0.7% | $449M+4.6% | $429.1M+1.4% | $423.3M+2.4% | $413.2M+5.6% | |
| Rest of world | $257.4M-1.6% | $261.7M-0.7% | $263.5M-0.2% | $263.9M-1.2% | $267.2M-0.9% | |
| United States | $1.43B+1.6% | $1.41B+1.2% | $1.39B+6.8% | $1.3B+4.3% | $1.25B+3.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does The Cooper Companies, Inc. break its business down?
- The Cooper Companies, Inc. (COO) reports net sales by business across 2 parts — Coopersurgical Segment and Coopervision Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does The Cooper Companies, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in The Cooper Companies, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
